Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in golgi vesicles

Cytometry

Volumn 41, Issue 1, 2000, Pages 62-72

  Merlin, Jean Louis ^a   Bour Dill, Corinne ^a   Marchal, Sophie ^a   Ramacci, Carole ^a   Poullain, Marie Gwenaelle ^b   Giroux, Bruno ^b  

^a CENTRE ALEXIS VAUTRIN   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Anthracyclines; Daunorubicin; Multidrug resistance; P glycoprotein; PSC833; S9788

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; DAUNORUBICIN; GLYCOPROTEIN; MULTIDRUG RESISTANCE PROTEIN; VALSPODAR;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG TRANSPORT; FLOW CYTOMETRY; FLUORESCENCE; GOLGI COMPLEX; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BETA 2-MICROGLOBULIN; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CYCLOSPORINS; DAUNORUBICIN; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GOLGI APPARATUS; HUMANS; MICROSCOPY, FLUORESCENCE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHENOTYPE; PIPERIDINES; TRIAZINES; TUMOR CELLS, CULTURED; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0034284484     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0320(20000901)41:1<62::AID-CYTO9>3.0.CO;2-7     Document Type: Article

References (37)

1. The biochemistry of P-glycoprotein-mediated multidrug resistance
2. Evidence for a cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers
3. Cytometric study of intracellular P-gp expression and reversal of drug resistance
4. Immunochemical detection of the multidrug resistance associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies
5. Overexpression of a Mr 110,000 vesicular protein in non-P-Glycoprotein-mediated multidrug resistance
6. Amplification and expression of the ABC transporters ARA and MRP in a series of multidrug-resistant leukaemia cell sublines
7. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells
8. Comparative evaluation of S9788, verapamil and cyclosporin A in K562 human leukemia cell lines and in P-glycoprotein expressing samples from patients with hematological malignancies
9. In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative
10. In vivo circumvention of P-glycoprotein mediated multidrug resistance of tumor cells with SDZ-PSC 833
11. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833
12. SDZ PSC833, a non immunosuppressive cyclosporine: Its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia
13. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia
14. Phase I trial of PSC 833 and doxorubicin, vincristine, cyclophosphamide, and prednisone (DVCP) in patients with refractory non-Hodgkin's lymphoma
15. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study
16. S9788 a multidrug resistance (MDR) reversing agent: French phase I studies with a 6 hour continuous infusion schedule in combination with chemotherapy in patients with refractory cancer
17. Subcellular distribution of daunorubicin in P-glycoprotein-positive and negative-drug resistant cell lines using laser-assisted confocal microscopy
18. Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug resistant MCF-7 cells using fluorescence microscopy image analysis
19. Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells
20. Increased plasma membrane traffic in daunorubicin resistant P388 leukemia cells. Effect of daunorubicin and verapamil
21. Quantitative cytological study of the activity of a new resistance modulator, S9788, on human leukemic cells using multiparametric image analysis
22. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL
23. Effect of combinations of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR gene expressing cells
24. Daunorubicin-induced apoptosis: Triggering of ceramide generation through sphingomyelin hydrolysis
25. Alteration of the daunorubicin-triggered sphingomyelin-ceramide pathway and apoptosis in MDR cells: Influence of drug transport abnormalities
26. SDZ-PSC833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells
27. Modulation of daunorubicin subcellular distribution in multidrug resistant MCF-7 cells by SDZ-PSC 833
28. Decreased mutation rates for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC833
29. Similar biochemical changes in human breast cancer cells and in carcinogen-induced resistance to xenobiotics
30. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction
31. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma
32. Antiproliferative activity of thermosensitive liposome-encapsulated doxorubicin combined with 43°C hyperthermia in sensitive and multidrug resistant MCF-7 cells
33. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
34. Increased accumulation of drugs in a multidrug resistant cell line by alteration of membrane potential properties
35. Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line
36. Probenecid reverses resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein overexpressing HL60/TAX and P388/ADR cells
37. P-glycoprotein in the golgi apparatus of multidrug-resistant cells